Pulse Biosciences, Inc. (PLSE) Bundle
Understanding Pulse Biosciences, Inc. (PLSE) Revenue Streams
Understanding Pulse Biosciences, Inc.’s Revenue Streams
Revenue Sources: As of September 30, 2024, Pulse Biosciences, Inc. reported $0 in product revenues for both the nine-month periods ended September 30, 2024 and 2023. The company has not generated any significant revenue from product sales since inception. The total revenues reported were also $0 for these periods.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the nine-month period ending September 30, 2024, compared to the same period in 2023, reflects a 0% change, as the total revenues remained $0.
Contribution of Different Business Segments to Overall Revenue
Currently, there are no contributions from different business segments to overall revenue, as the company operates without generating revenue from product sales.
Significant Changes in Revenue Streams
There have been no significant changes in revenue streams, as the company continues to report $0 in product revenues over the comparative periods. The reliance on financing activities rather than product sales has been consistent, with the company focusing on research and development.
| Period | Product Revenues | Total Revenues | Year-over-Year Change (%) |
|---|---|---|---|
| September 30, 2024 | $0 | $0 | 0% |
| September 30, 2023 | $0 | $0 | 0% |
As of September 30, 2024, the company reported a net loss of $34.2 million compared to a net loss of $30.3 million for the same nine-month period in 2023, representing an increase in loss by $3.9 million. The increase is primarily attributed to higher research and development costs.
A Deep Dive into Pulse Biosciences, Inc. (PLSE) Profitability
Profitability Metrics
Gross Profit Margin: For the nine months ended September 30, 2024, the company reported $0 in total revenues, resulting in a gross profit margin of 0%.
Operating Profit Margin: The loss from operations for the same period was $(35,996,000), leading to an operating profit margin of (∞)% (as there are no revenues).
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was $(34,200,000), resulting in a net profit margin of (∞)% due to the absence of revenues.
Trends in Profitability Over Time
Comparing the nine months ended September 30, 2024, to the same period in 2023, the following trends are observed:
| Metric | 2024 | 2023 | $ Change |
|---|---|---|---|
| Total Revenues | $0 | $0 | $0 |
| Loss from Operations | $(35,996,000) | $(31,041,000) | $(4,955,000) |
| Net Loss | $(34,200,000) | $(30,277,000) | $(3,923,000) |
Comparison of Profitability Ratios with Industry Averages
The profitability ratios are significantly lower than industry averages, where typical gross profit margins in the biotechnology sector range from 60% to 80%. The operating and net profit margins are negative, which is common in early-stage biotech firms, but the absence of revenue indicates a critical need for operational changes.
Analysis of Operational Efficiency
Operational efficiency can be assessed through cost management and gross margin trends. The primary expenses for the nine months ended September 30, 2024, were:
| Category | 2024 (in thousands) | 2023 (in thousands) | $ Change |
|---|---|---|---|
| Research and Development | $21,674 | $19,998 | $1,676 |
| General and Administrative | $14,322 | $11,043 | $3,279 |
| Total Costs and Expenses | $35,996 | $31,041 | $4,955 |
The increase in research and development expenses by $1,676,000 and general administrative expenses by $3,279,000 reflects a focus on product development and operational management but also indicates rising operational costs without corresponding revenue generation.
Debt vs. Equity: How Pulse Biosciences, Inc. (PLSE) Finances Its Growth
Debt vs. Equity: How Pulse Biosciences, Inc. Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, the company had a total debt of $0, down from $65 million in the previous year following the extinguishment of the 2022 Loan Agreement. The previous debt consisted of a term loan with Robert W. Duggan, which bore interest at a rate of 5.0% annually.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio stands at 0.00 as of September 30, 2024, indicating that the company has no outstanding debt. This is significantly lower than the industry average debt-to-equity ratio of approximately 0.50, suggesting a conservative approach to leveraging.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
No recent debt issuances have occurred since the 2022 Loan Agreement was terminated in April 2023. The company has shifted its financing strategy towards equity, particularly through rights offerings. The last significant equity issuance was the 2024 Rights Offering, which raised $60 million.
How the Company Balances Between Debt Financing and Equity Funding
The financing strategy has transitioned primarily to equity funding, with the company generating approximately $61.9 million from financing activities in the nine months ended September 30, 2024. This includes proceeds from the 2024 Rights Offering and exercise of stock options.
| Type of Financing | Amount (in millions) | Details |
|---|---|---|
| Debt | $0 | Term loan extinguished in 2023 |
| Equity (2024 Rights Offering) | $60 | Sale of 6 million units at $10/unit |
| Equity (2023 Private Placement) | $65 | Common stock issued to major stockholder |
| Net Cash from Financing Activities | $61.9 | For nine months ended September 30, 2024 |
In summary, the company has effectively eliminated its debt, relying on equity financing to support growth and maintain financial flexibility in a capital-intensive industry.
Assessing Pulse Biosciences, Inc. (PLSE) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
The current ratio for Pulse Biosciences, Inc. as of September 30, 2024, is calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $79.0 million | $6.7 million | 11.79 |
The quick ratio, considering only the most liquid assets, is:
| Quick Assets | Current Liabilities | Quick Ratio |
|---|---|---|
| $78.9 million | $6.7 million | 11.77 |
Analysis of Working Capital Trends
As of September 30, 2024, the working capital is:
| Current Assets | Current Liabilities | Working Capital |
|---|---|---|
| $79.0 million | $6.7 million | $72.3 million |
This represents a significant increase compared to previous periods, indicating a strong liquidity position.
Cash Flow Statements Overview
The cash flow statements for the nine months ended September 30, 2024, reflect the following trends:
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Operating Activities | $(27,199) | $(26,259) |
| Investing Activities | $(72) | $(78) |
| Financing Activities | $61,939 | $15,584 |
| Net Increase in Cash | $34,668 | $(10,753) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company has cash and cash equivalents of $79.0 million. This amount is projected to be sufficient to fund operating requirements for at least the next twelve months. However, the company plans to raise additional capital in the future, indicating potential liquidity concerns if financing is not secured on favorable terms.
The reliance on external financing through equity offerings or debt may present risks, particularly if market conditions change or investor sentiment shifts. The significant cash provided by financing activities in 2024 underscores the company's ability to attract capital when needed, but the ongoing need for additional financing remains a critical factor in assessing long-term liquidity and solvency.
Is Pulse Biosciences, Inc. (PLSE) Overvalued or Undervalued?
Valuation Analysis
As of 2024, the valuation metrics for the company indicate various ratios that help assess whether it is overvalued or undervalued. The following key ratios are analyzed:
- Price-to-Earnings (P/E) Ratio: The P/E ratio is currently not applicable as the company reported a net loss of $34.2 million for the nine months ended September 30, 2024, resulting in a basic and diluted net loss per share of $(0.60).
- Price-to-Book (P/B) Ratio: The book value of equity as of September 30, 2024, is $79.1 million with 61.5 million shares outstanding, leading to a P/B ratio of approximately 1.00.
- Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: Given the lack of positive EBITDA, this ratio is not computable. The company reported total revenues of $0 for the nine months ended September 30, 2024.
The stock price trends over the last 12 months have shown volatility. As of September 30, 2024, the stock was trading at approximately $10.00 per share, which reflects a significant increase from lows of $2.05 post the 2022 Rights Offering.
Stock Price Trends
| Date | Stock Price | Change (%) |
|---|---|---|
| October 2023 | $2.50 | N/A |
| January 2024 | $5.00 | 100% |
| April 2024 | $8.00 | 60% |
| July 2024 | $10.00 | 25% |
Regarding dividends, the company has not declared any dividends and has a payout ratio of 0% due to the net losses incurred.
Analyst Consensus on Stock Valuation
- Analysts currently have a consensus rating of Hold on the stock.
- Price targets from analysts range from $7.00 to $12.00.
- Recent analyst reports suggest caution due to ongoing operational losses and reliance on future capital raises.
In summary, the financial health of the company illustrates significant operating losses with no current profitability, leading to cautious investor sentiment reflected in the analyst consensus.
Key Risks Facing Pulse Biosciences, Inc. (PLSE)
Key Risks Facing Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. faces several internal and external risks that could significantly impact its financial health and operational viability.
Industry Competition
The medical technology industry is highly competitive, with numerous established players and new entrants constantly emerging. The inability to keep pace with technological advancements and market trends may hinder the company's growth. The risk of not achieving sufficient market penetration for its CellFX technology, which addresses various dermatological conditions, poses a significant threat to future revenue generation.
Regulatory Changes
Changes in regulations governing medical devices can impact product approval timelines and market access. The company has not yet generated significant revenues from product sales, and any delays in regulatory approvals could prolong this trend. The approval process is often lengthy and uncertain, which adds a layer of risk to the company's operational plans.
Market Conditions
Economic downturns and fluctuations in healthcare spending can adversely affect the company's revenue potential. The ongoing geopolitical tensions, such as conflicts in the Middle East and Ukraine, as well as high interest rates, could further constrain funding opportunities and market conditions for new medical technologies.
Operational Risks
The company has reported significant operating losses, with a net loss of $34.2 million for the nine months ended September 30, 2024, compared to a net loss of $30.3 million in the same period of 2023. Research and development expenses have risen to $21.7 million for the same period, indicating a substantial investment in product development without corresponding revenue growth. The reliance on equity financing and loans to fund operations poses a risk of dilution for existing shareholders and potential liquidity issues if future funding is not secured.
Financial Risks
The company has historically funded its operations through the issuance of equity and debt. As of September 30, 2024, it had cash and cash equivalents of $79.0 million. However, the lack of sustainable revenue generation raises concerns about the adequacy of its liquidity to meet future cash requirements. The company expects to incur additional losses for the next several years, which could limit its ability to raise capital and maintain operational stability.
Mitigation Strategies
To address these risks, the company has indicated plans to invest in research and development to develop commercially viable products and assess potential future products. As of September 30, 2024, the company is pursuing additional financing options to support its operations and growth initiatives. The recent 2024 Rights Offering generated gross proceeds of $60 million, which could provide some buffer against immediate financial pressures.
| Risk Factor | Description | Impact | Mitigation Strategies |
|---|---|---|---|
| Industry Competition | High competition from established and new entrants | Potential loss of market share | Continuous R&D investment |
| Regulatory Changes | Changes in medical device regulations | Delays in product approvals | Engagement with regulatory bodies |
| Market Conditions | Economic downturns affecting healthcare spending | Reduced revenue potential | Diverse revenue streams and cost management |
| Operational Risks | Significant operating losses and R&D costs | Liquidity concerns | Secure additional financing |
| Financial Risks | Reliance on equity and debt for funding | Risk of dilution and financial instability | Monitor cash flow and manage expenses |
Future Growth Prospects for Pulse Biosciences, Inc. (PLSE)
Future Growth Prospects for Pulse Biosciences, Inc.
Analysis of Key Growth Drivers
Pulse Biosciences, Inc. is poised for growth driven by multiple factors including product innovations, market expansions, and strategic partnerships. The company has focused on enhancing its proprietary technology, which has shown potential in dermatology and may expand into cardiology and other medical fields.
Revenue Growth Projections and Earnings Estimates
As of September 30, 2024, the company reported total revenues of $0, with product revenues remaining at $0 for both the nine-month periods ended September 30, 2024, and 2023. Despite this, the company is investing heavily in research and development, with expenses increasing to $21.7 million for the nine-month period ended September 30, 2024, compared to $20.0 million in the same period of 2023. Analysts project that as new products are developed and brought to market, the company may achieve significant revenue growth over the next few years.
Strategic Initiatives and Partnerships
The company has undertaken strategic initiatives to bolster its market position. In July 2024, it closed a rights offering that generated $60 million in gross proceeds. This capital will be utilized to fund ongoing research and development efforts aimed at creating new products and enhancing existing offerings. Additionally, the company has received approximately $1.5 million from the exercise of warrants issued during its 2024 Rights Offering.
Competitive Advantages
Pulse Biosciences maintains several competitive advantages, including its unique NPS technology, which differentiates its products in the medical technology landscape. The company has built a strong intellectual property portfolio, which supports its innovation efforts. As of September 30, 2024, the company had cash and cash equivalents of $79.0 million, providing a solid financial foundation to support its growth initiatives.
| Metric | 2024 (9 Months) | 2023 (9 Months) | $ Change |
|---|---|---|---|
| Total Revenues | $0 | $0 | $0 |
| Research and Development Expenses | $21.7 million | $20.0 million | $1.7 million |
| General and Administrative Expenses | $14.3 million | $11.0 million | $3.3 million |
| Net Loss | $(34.2 million) | $(30.3 million) | $(3.9 million) |
| Cash and Cash Equivalents | $79.0 million | $50.4 million | $28.6 million |
Overall, while the company has yet to generate significant revenues, its focus on research and development, combined with strategic financing initiatives and its proprietary technology, position it well for future growth in the medical technology market.
Pulse Biosciences, Inc. (PLSE) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Pulse Biosciences, Inc. (PLSE) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Pulse Biosciences, Inc. (PLSE)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Pulse Biosciences, Inc. (PLSE)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.